After uncovering a handful of patient safety and cybersecurity risks in many of its infusion pumps over the last year, Baxter has now begun a recall of yet another product that works alongside those pumps.

All roads lead to fibrosis, at least when it comes to chronic inflammation. The condition can occur almost anywhere in the body where inflammation is present, driven by the abnormal growth of activated fibroblasts—collagen-secreting cells found in connective tissue—which build up in organs, hardening them.

Researchers at New York University (NYU) have developed a single test they say can help determine which patients are most likely to see their cancer return after treatment with immunotherapies as well as who may be at risk for severe side effects.

Smith+Nephew already has data showing its regenerative implant for rotator cuff surgery can help foster the growth of new, tendon-like tissues. Now, a randomized trial has shown those repairs can be strong enough to last for a year.

Alnylam and Regeneron have hit the gas on their RNAi nonalcoholic steatohepatitis (NASH) program, outlining plans to kick off a phase 2 clinical trial of the drug candidate after generating early evidence of efficacy.

Blood stem cell donors are in chronic short supply, posing problems for patients whose blood stem cells have been depleted by chemotherapy or who have diseases like aplastic anemia. Donor cells used in transplantation must be tissue-matched to patients, so those who come from minority ethnic backgrounds often struggle to find a compatible donor. And even when donor cells are successfully engrafted, there is no guarantee that the patient’s body won’t reject them.

Eloxx Pharmaceuticals’ cystic fibrosis candidate has failed a midphase clinical trial, dragging its battered share price down further still and leaving the future of the program in doubt.

Strata Oncology, developer of a range of DNA- and RNA-based tests as well as a genomic and transcriptomic profiling platform, is extending its clinical collaboration with Pfizer assessing multiple approved cancer therapies.

BioIVT, a biological specimens and services firm, has snapped up Sekisui Chemical’s CRO division XenoTech for an undisclosed price.

Close to 4 million babies are born in the U.S. every year, and within their first 48 hours nearly all are pricked in the heel so their blood can be tested for dozens of life-threatening genetic and metabolic problems. The heel-stick test is considered such a crucial public health measure that states typically require it, and parents aren’t asked for their permission before it’s done.